PARP inhibitors (olaparib, rucaparib, niraparib, and talazoparib) are a prime example of precision medicine, as they selectively target cancer cells with DNA repair deficiencies, such as BRCA1/2 mutations, leading to increased genomic instability and cell death [152]. This evidence concerns the gene PARP1 and cancer.